Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
36 studies found for:    Open Studies | "Cerebellar Diseases"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Emotional Communication Disorders in Cerebellar Disease
Condition: Cerebellar Diseases
Interventions: Behavioral: Testing of emotional communication ability;   Procedure: magnetic resonance imaging (MRI) of the brain
2 Not yet recruiting Citocoline for Treatment of FXTAS
Condition: Balance and Cognitive Deficits in Fragile X-associated Tremor Ataxia Syndrome
Intervention: Drug: citocoline
3 Unknown  Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome
Conditions: Fragile X-Associated Tremor/Ataxia Syndrome;   Fragile X Premutation Carriers
Intervention: Drug: Memantine
4 Recruiting A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
5 Recruiting The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease
Condition: Machado Joseph Disease (SCA3)
Intervention: Device: Deep TMS
6 Unknown  Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)
Conditions: Ataxia Telangiectasia;   Growth Failure
Intervention: Drug: Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
7 Recruiting Parkinsonism in Spinocerebellar Ataxia Type 6
Condition: Spinocerebellar Ataxia Type 6
Intervention:
8 Recruiting A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose;   Drug: Placebo
9 Recruiting An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
10 Recruiting Impact of Cerebellar Mass Resection on Pain Processing in Pediatric Patients
Condition: Cerebellar Neoplasm
Interventions: Device: Medoc Advanced Medical Systems PATHWAY Model ATS (Contact thermal stimulator);   Procedure: Cold water bath;   Device: MRI scanner;   Other: Questionnaires
11 Unknown  Efficacy of Riluzole in Hereditary Cerebellar Ataxia
Condition: Cerebellar Ataxia
Interventions: Drug: riluzole;   Other: Placebo comparator
12 Recruiting An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia
Condition: Friedreich's Ataxia
Intervention: Drug: Acetyl-L-Carnitine
13 Recruiting Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease
Condition: Machado-Joseph Disease / Spinocerebellar Ataxia 3
Intervention: Drug: Cabaletta for IV infusion once weekly during 24 weeks
14 Unknown  Cerebellum - Cognitive Outcome and Functional Connectivity
Condition: Childhood Cerebellar Tumor
Intervention:
15 Not yet recruiting Pancreatic Cancer Screening of High-Risk Residents of Arkansas
Conditions: Pancreatic Neoplasms;   Peutz-Jegher's Syndrome;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Ataxia Telangiectasia;   Familial Atypical Mole-Malignant Melanoma Syndrome;   Colorectal Neoplasms, Hereditary Nonpolyposis;   Hereditary Pancreatitis
Intervention: Other: Pancreatic Cancer Screening
16 Recruiting Machado-Joseph Disease in Israel
Condition: Spinocerebellar Ataxia 3
Intervention:
17 Unknown  Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients
Condition: Ataxia Telangiectasia
Interventions: Biological: Prevenar® (7-valent pneumococcal conjugate vaccine);   Biological: Pneumovax® (pneumococcal polysaccharide vaccine)
18 Recruiting Oxidative Stress, Low Grade Inflammation, Tissue Breakdown and Biomarkers in Cerebrospinal Fluid of A-T
Condition: Ataxia Telangiectasia
Intervention: Procedure: Lumbar puncture
19 Recruiting RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe
Condition: Friedreich Ataxia
Interventions: Drug: RTA 408 Capsules, 2.5 mg;   Drug: RTA 408 Capsules, 5 mg;   Drug: RTA 408 Capsules, 10 mg;   Drug: Placebo
20 Recruiting Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia
Condition: Friedreich's Ataxia
Interventions: Drug: VP 20629;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years